Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment
Pharmaceutics · 20.09.2024 · 16 (9) · 1228
DOI: 10.3390/pharmaceutics16091228 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 20.09.2024. Verfasst von Xuejia Kang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Materials Research and Education Center, Materials Engineering, Department of Mechanical Engineering, Auburn University, Auburn, AL 36849, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH MIRA R35GM133795, NIH HHS.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking treatment for hematological cancers, yet it faces significant hurdles, particularly regarding its efficacy in solid tumors and concerning associated adverse effects. This review provides a comprehensive analysis of the advancements and ongoing challenges in CAR-T therapy. We highlight the transformative potential of nanotechnology in enhancing CAR-T therapy by improving targeting precision, modulating the immune-suppressive tumor microenvironment, and overcoming physical barriers. Nanotechnology facilitates efficient CAR gene delivery into T cells, boosting transfection efficiency and potentially reducing therapy costs. Moreover, nanotechnology offers innovative solutions to mitigate cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Cutting-edge nanotechnology platforms for real-time monitoring of CAR-T cell activity and cytokine release are also discussed. By integrating these advancements, we aim to provide valuable insights and pave the way for the next generation of CAR-T cell therapies to overcome current limitations and enhance therapeutic outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Materials Research and Education Center, Materials Engineering, Department of Mechanical Engineering, Auburn University, Auburn, AL 36849, USA.
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.
- Faculty of Pharmacy, Mulawarman University, Samarinda 75119, Kalimantan Timur, Indonesia.
ORCID-Profile: Xuejia Kang, Nur Mita, Zongliang Yue, R Jayachandra Babu, Pengyu Chen
Förderung
- NIGMS NIH HHS
- NIH MIRA R35GM133795
- NIH HHS
- Auburn University
- NIH
Zitieren
APA
Kang, X., Mita, N., Zhou, L., Wu, S., Yue, Z., Babu, R. J., & Chen, P. (2024). Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment. Pharmaceutics, 16(9), 1228. https://doi.org/10.3390/pharmaceutics16091228
Vancouver
Kang X, Mita N, Zhou L, Wu S, Yue Z, Babu RJ, et al. Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment. Pharmaceutics. 2024;16(9):1228. doi:10.3390/pharmaceutics16091228
BibTeX
@article{Kang2024,
author = {Kang, Xuejia and Mita, Nur and Zhou, Lang and Wu, Siqi and Yue, Zongliang and Babu, R Jayachandra and Chen, Pengyu},
title = {Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {9},
pages = {1228},
doi = {10.3390/pharmaceutics16091228}
}
EUVIMED